Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
BioSpace8d
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Yahoo Finance8d
Novo Nordisk plans new study for CagriSema, targets 2026 submission
A 68-week Phase III study like REDEFINE 1, REDEFINE 2 is evaluating CagriSema in type 2 diabetes patients who are also either obese or overweight. Novo Nordisk’s CEO Lars Fruergaard Jorgensen ...
AOL10d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
The company's shares were up 4.2% at 1527 GMT. The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly ...